DXCM, based in San Diego, California, is an emerging medical device company focused on the design and development of continuous glucose monitoring(CGM) systems for people with diabetes. The company is currently engaged in the development of two continuous glucose-monitoring systems: a short-term system with a sensor that can be inserted by a patient, and a long-term system with a sensor that can be implanted by a physician. A key element of DXCM's monitoring system technology is the continuous measure of patient's blood glucose level and the real-time transmission of that information to a small cell phone-sized receiver. DXCM's monitoring systems aim to provide real-time continuous blood glucose values, trend data and alert patients to assist in managing their blood glucose levels. In contrast, currently available self-monitoring systems use disposable test strips to test blood sampled at discrete points in time.
The company was founded in 1999 and listed on April 19, 2005 through the issue of 4,700,000 shares of common stock, raising $52.5M. DXCM has eight issued U.S. patents expiring between 2006 and 2021, and 60 additional U.S. patent applications pending. In 1Q06 DXCM received Food and Drug Administration (FDA) approval for its STS Continuous Glucose Monitoring System, which was subsequently launched nationally on March 28, 2006.
The SEVEN System is presented as an alternative to the "finger-stick" method of glucose monitoring. By using continuous glucose monitoring(CGM) individuals who would normally monitor their levels via infrequent testing throughout the day can track their glucose levels as a trend from moment to moment. The SEVEN System is made up of three components: the sensor, the transmitter and the receiver; and are designed to be small, unobtrusive, and lightweight. Comparison with competitive products can be viewed below in "Competition."
Designed to analyze downloaded data from the SEVEN receiver, DexCom's diabetes management software provides users to track their trends and progress over time. This includes the ability to plot CGM values across several days and overlaid on the target range for comprehensive lifestyle evaluation.
|||DexCom SEVEN System||Freestyle Navigator||Guardian RT|
|Hypo-Safety-Alarm||Yes, less than or equal to 55 mg/dL (Cannot be turned off)||No||No|
|Sensor life||Up to 7 days||Up to 5 days||Up to 3 days|
|Sensor warm-up time after calibration||2 hours||10 hours||2 hours|
|Average lag time||5 minutes||14 minutes||Not documented|
|Calibration (minimum requirement)||Twice a day||4 times over 5 days||Twice a day|
|Introducer needle size (diameter)||.5mm (26 gauge)||.72mm (21 gauge)||.65mm (22 gauge)|
|Transmitter weight||6.8 grams||13.6 grams||7.1 grams|
|Transmitter power||Built in and lasts for life of Transmitter (1.5 Years)||Battery cell must be replaced||Rechargeable|
|Receiver power||Rechargeable||Battery lasts about 30 days||Battery lasts about 2 to 4 weeks|
|Calibration restrictions||Accepts calibration values between 40-400 mg/dL||Accepts calibration values between 60-300 mg/dL. No calibrations during or around meals, exercise, or while sleeping.||Accepts calibration values between 40-400 mg/dL. No calibrations with changing glucose values.|